Abstract:We propose an adaptive sequential testing procedure for the selection and testing of multiple treatment options, such as dose/regimen, different drugs, sub-populations, endpoints, or a mixture of them in a seamlessly combined phase II/III trial. The selection is to be made at the end of phase 2 stage. Unlike in many of the published literature, the selection rule is not required to be to "select the best", and does not need to be pre-specified, which provides flexibility and allows the trial investigators to use any efficacy and safety information/criteria, or surrogate or intermediate endpoint to make the selection. Sample size and power calculations are provided. The calculations have been confirmed to be accurate by simulations. Interim analysis can be performed after the selection, sample size can be modified if the observed efficacy deviates from the assumed. Inference after the trial, including p-value, median unbiased point estimate and confidence intervals, are provided. By applying a dominance theorem, the procedure can be applied to normal, binary, Poisson, negative binomial distributed endpoints and time-to-event endpoints, and a mixture of these distributions (in trials involving endpoint selection).
What problem does this paper attempt to address?
This paper attempts to solve the problem of how to effectively combine Phase II and Phase III trials in clinical trial design, especially how to make flexible selections and tests in a seamless design when choosing treatment regimens (such as dose/administration mode, different drugs, sub - populations, endpoints or combinations of these). Specifically, the paper proposes an Adaptive Two - Stage Seamless Sequential Design (ATSSSD), aiming to solve the following key issues:
1. **Family - Wise Error Rate (FWER) Control**: Since it is necessary to select one from multiple treatment options to enter Phase III at the end of the Phase II stage, this process is essentially a multiple - comparison problem. The method proposed in the paper controls FWER by using the dominance theorem to ensure that it does not exceed the nominal level and can be equal to the nominal level under certain conditions.
2. **Data Integration**: How to effectively integrate Phase II and Phase III data is a major challenge because Phase II data do not follow a normal distribution due to the selection process. The method proposed in the paper directly adds the score functions of Phase II and Phase III to form a Markov process, thus retaining the exact description of Phase II data and avoiding conservative data transformation.
3. **Sample Size and Power Calculation**: These calculations are crucial for trial planning, but sample size and power calculations become complicated due to multiple comparisons and complex data integration methods. The paper provides accurate sample size and power calculation methods and verifies the accuracy of these calculations through simulation.
4. **Adaptive Measures**: The assumed effect size may be inaccurate, so adaptive measures (such as sample size re - estimation) may be necessary. The method proposed in the paper includes sample size re - estimation in the Phase III stage to improve power.
5. **Statistical Inference**: Statistical inference needs to be carried out after the trial is completed, including p - values, effect size estimation and confidence intervals. The paper provides a method that can perform unbiased estimation and accurate inference after selection, and the relevance and importance of the inference will not be reduced even if adaptive adjustments are made.
6. **Flexibility of Selection Rules**: Unlike other methods, the method proposed in the paper does not require "play - the - winner", but allows trial researchers to make selections based on any efficacy and safety information/standards or surrogate/intermediate endpoints. This provides greater flexibility for selection.
In conclusion, by proposing a new Adaptive Two - Stage Seamless Sequential Design method, this paper solves the key problems of how to effectively combine Phase II and Phase III trials in clinical trial design, improves the efficiency and flexibility of the trial, and at the same time ensures statistical rigor and accuracy.